KENNEY CHRISTOPHER JOHN — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
KENNEY CHRISTOPHER JOHN is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $244K.
Profile
Christopher John Kenney is the Chief Medical Officer of Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company. Based on the SEC filing with CIK 0001880129 dated 2026-01-09, he serves as the company's Chief Medical Officer; the filing shows no purchases or sales in that period. In this role, he is responsible for medical strategy and clinical development across Xenon's neuroscience pipeline, which includes XEN1101, NBI-921352, and XEN496 for epilepsy and related conditions.
Role
Insider
Notability
40/100
Board memberships
Xenon Pharmaceuticals Inc.
Awards & honors
Oversees clinical development and medical affairs for Xenon's neuroscience portfolio
Guides medical strategy for XEN1101, NBI-921352, and XEN496
Supports regulatory interactions and trial design as Chief Medical Officer
Christopher John Kenney is the Chief Medical Officer of Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company. Based on the SEC filing with CIK 0001880129 dated 2026-01-09, he serves as the company's Chief Medical Officer; the filing shows no purchases or sales in that period. In this role, he is responsible for medical strategy and clinical development a…
Has KENNEY CHRISTOPHER JOHN been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($244K) across all tracked filings.
Where can I see all of KENNEY CHRISTOPHER JOHN's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
